LifeMD’s (LFMD) Buy Rating Reiterated at BTIG Research

LifeMD (NASDAQ:LFMD)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a research note issued on Monday,Benzinga reports. They currently have a $10.00 target price on the stock. BTIG Research’s target price would suggest a potential upside of 100.00% from the company’s previous close.

LFMD has been the topic of a number of other reports. Cantor Fitzgerald restated an “overweight” rating on shares of LifeMD in a research report on Tuesday, March 10th. Weiss Ratings restated a “sell (e+)” rating on shares of LifeMD in a research report on Friday, March 27th. HC Wainwright boosted their price target on shares of LifeMD from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Loop Capital set a $10.00 price target on shares of LifeMD in a research report on Thursday, March 12th. Finally, Wall Street Zen upgraded shares of LifeMD from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, LifeMD currently has a consensus rating of “Moderate Buy” and an average price target of $9.14.

LifeMD Price Performance

Shares of NASDAQ LFMD opened at $5.00 on Monday. The company’s 50-day simple moving average is $3.74 and its 200-day simple moving average is $3.96. LifeMD has a 52-week low of $2.56 and a 52-week high of $15.84. The firm has a market cap of $239.85 million, a price-to-earnings ratio of 19.23 and a beta of 2.03.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). The business had revenue of $46.87 million for the quarter, compared to analyst estimates of $48.57 million. LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%. Equities research analysts anticipate that LifeMD will post 0.01 EPS for the current fiscal year.

Hedge Funds Weigh In On LifeMD

Institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in LifeMD by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after acquiring an additional 2,235 shares during the last quarter. Creative Planning acquired a new stake in LifeMD during the second quarter worth $272,000. JPMorgan Chase & Co. increased its stake in LifeMD by 581.2% during the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock worth $5,619,000 after acquiring an additional 352,004 shares during the last quarter. Legal & General Group Plc increased its stake in LifeMD by 187.4% during the second quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock worth $138,000 after acquiring an additional 6,614 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in LifeMD by 8.7% during the second quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock worth $730,000 after acquiring an additional 4,281 shares during the last quarter. 35.52% of the stock is owned by hedge funds and other institutional investors.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.